Augmentin price in the United States depends on the exact prescription product, dosage form, strength, dispensing quantity and payment method. Standard branded Augmentin contains amoxicillin and clavulanate potassium and is available in FDA-labeled conventional tablets, chewable tablets and oral suspensions. These formulations differ in their active-component quantities, package characteristics and administration requirements. Consequently, a price quoted for Augmentin 875 mg/125 mg tablets does not describe the cost of 500 mg/125 mg tablets or a bottle of oral suspension. A meaningful cost comparison begins with the complete prescription identity rather than the brand name alone.
Brand Augmentin costs should also be distinguished from generic amoxicillin/clavulanate prices. U.S. pharmacy search tools may display the familiar Augmentin name while showing a lower generic cash or discount-card amount. Insurance benefits, pharmacy networks and discount programs can further change what a patient ultimately pays. A published price is not automatically a current pharmacy offer, and FDA approval does not guarantee that the original branded product is stocked. For this reason, this guide explains pricing factors and verification methods without publishing dollar amounts that could become outdated or misrepresent branded availability.
For patients comparing an existing prescription, the most useful approach is to confirm whether the medicine is brand Augmentin or an approved generic, identify both active-component strengths, verify the dosage form and prescribed quantity, and request a pharmacy-specific quotation under the applicable payment method. Any change in product or formulation must be reviewed professionally rather than selected solely to lower the price. This page addresses standard branded Augmentin costs; generic amoxicillin/clavulanate pricing and Augmentin insurance coverage are covered separately.
The retail cost of branded Augmentin reflects several factors rather than one nationally uniform price. The relevant product, quantity, pharmacy, insurance arrangement and discount eligibility can all affect the amount charged. A quotation for one prescription should not be applied automatically to a different strength or dispensing location.
Augmentin is a proprietary brand containing amoxicillin and clavulanate potassium. The two active ingredients must be identified together because plain amoxicillin is a different medicine. Branded Augmentin also includes multiple immediate-release dosage forms with different strengths and package configurations. The exact item matters before a meaningful comparison can begin.
Another important distinction is between an original branded product and a generic marketed under the established name amoxicillin and clavulanate potassium. A pharmacy may display Augmentin as a recognizable reference name while quoting an available generic product. Such a quotation should be classified according to the medicine actually offered rather than the heading shown on a search page.
Brand availability can influence whether a pharmacy can provide a quotation for the intended product. FDA labeling establishes approved product characteristics, but it does not establish present distribution or stock at a particular pharmacy. A historical product listing may remain visible even when its commercial availability is uncertain.
The Augmentin brand overview explains the branded product family, while amoxicillin/clavulanate product information provides the broader two-ingredient medicine context. This cost guide focuses on how to interpret price quotations without suggesting a treatment or strength.
Conventional immediate-release Augmentin tablets have three FDA-labeled strength pairs: 250 mg/125 mg, 500 mg/125 mg and 875 mg/125 mg. The first quantity is amoxicillin and the second is clavulanic acid. These strengths represent different prescription products, so their prices should be considered separately.
The quantity of tablets also matters. A quotation for one tablet count cannot be assumed to apply proportionately to every other quantity. Pharmacy dispensing practices, original package configurations, product availability and payment rules can influence the final charge.
The strength pairs must not be treated as interchangeable based on price. The conventional 250 mg/125 mg tablet contains 125 mg of clavulanic acid, so two such tablets provide a different clavulanate total from one 500 mg/125 mg tablet. FDA labeling specifically restricts this substitution. A cheaper-looking combination of strengths is therefore not a valid self-directed cost-saving method.
When comparing brand tablet quotations, patients should confirm that the pharmacy is quoting the original Augmentin brand, not a generic alternative. The strength, tablet count and payment method should also match the prescription. If a brand-specific product is not available, a pharmacist can explain whether a legally and clinically appropriate alternative may be considered.
Detailed product characteristics belong in the Augmentin tablets guide and individual pages for 250/125 mg, 500/125 mg and 875/125 mg. This section addresses cost-comparison principles rather than clinical strength selection.
| Conventional tablet | Product distinction | Relevant pricing variables |
|---|---|---|
| 250 mg/125 mg | 250 mg amoxicillin plus 125 mg clavulanic acid | Original brand identity, prescribed tablet count, pharmacy and payment method. |
| 500 mg/125 mg | 500 mg amoxicillin plus 125 mg clavulanic acid | Exact strength, quantity, brand availability and pharmacy quotation. |
| 875 mg/125 mg | 875 mg amoxicillin plus 125 mg clavulanic acid | Exact strength, quantity, brand availability and applicable cash or insurance terms. |
Standard Augmentin oral suspension is supplied as powder for reconstitution and identified by the quantities of amoxicillin and clavulanic acid per 5 mL of prepared liquid. The FDA-labeled concentrations include 125 mg/31.25 mg, 200 mg/28.5 mg, 250 mg/62.5 mg and 400 mg/57 mg per 5 mL. These are separate product concentrations rather than alternative names for the same liquid.
Two variables are essential to any liquid price comparison: concentration and final prepared bottle volume. A quotation for one concentration cannot be used as the price of another concentration, even when the bottle volumes are identical. Likewise, bottles with the same concentration but different final volumes do not contain the same total quantity of medicine.
Pharmacies may dispense a product prepared from powder according to the manufacturer's labeling. The final prescribed volume, bottle configuration and dispensing arrangements can influence the quotation. Reconstitution and refrigerated-storage requirements are handling considerations, not reasons to change concentration without professional review.
Brand and generic liquids should be compared separately. An online result headed Augmentin suspension may refer to generic amoxicillin/clavulanate, and the exact product should be verified before treating the displayed amount as a branded price.
Augmentin ES-600 is a separate pediatric suspension containing 600 mg/42.9 mg per 5 mL and has distinct FDA-labeled characteristics. It should not be grouped with standard suspension prices. The standard Augmentin suspension guide covers concentration and package details, while Augmentin ES-600 addresses that specialized formulation.
| Standard liquid concentration | Labeled component ratio | Cost-comparison requirement |
|---|---|---|
| 125 mg/31.25 mg per 5 mL | 4:1 | Verify original brand, concentration and final prepared volume. |
| 200 mg/28.5 mg per 5 mL | Approximately 7:1 | Compare quotations for the same concentration and volume. |
| 250 mg/62.5 mg per 5 mL | 4:1 | Do not confuse with the conventional 250 mg/125 mg tablet. |
| 400 mg/57 mg per 5 mL | Approximately 7:1 | Confirm bottle quantity, product identity and pharmacy terms. |
Augmentin chewable tablets represent another distinct dosage form. FDA-labeled strength pairs include 125 mg/31.25 mg, 200 mg/28.5 mg, 250 mg/62.5 mg and 400 mg/57 mg per tablet. A chewable tablet should not be treated as a conventional film-coated tablet or oral suspension merely because the amoxicillin quantity is similar.
A pharmacy quotation for chewables should identify the exact strength, tablet count and brand or generic product. Chewable formulations can differ from conventional tablets in their component ratios, inactive ingredients and product-identification characteristics.
For example, the 250 mg/62.5 mg chewable contains less clavulanic acid than the conventional 250 mg/125 mg tablet. FDA labeling identifies those formulations as not interchangeable. Any apparent price advantage from changing dosage forms is therefore insufficient to justify substitution.
The Augmentin chewable tablets guide covers strengths, formulation differences and product verification. This price hub retains chewables as a separate comparison category without duplicating that detailed product catalog.
Brand Augmentin and generic amoxicillin/clavulanate may appear together in pharmacy search results, but their prices should be identified separately. The branded product carries the Augmentin proprietary name, while generic products use the established ingredient names and are approved under their relevant FDA applications.
An appropriately approved generic must meet applicable FDA requirements, including product-specific bioequivalence and pharmaceutical-equivalence standards. A generic may differ in appearance, packaging or certain inactive ingredients. Such differences do not automatically indicate inferior quality, but the correct dosage form and strength still must be verified.
Many pharmacy discount tools emphasize generic products because they can represent a different pricing category from the original brand. However, an advertised generic amount is not evidence that the same pharmacy offers branded Augmentin at that price. Brand availability and generic availability may also differ.
Whether a pharmacy may dispense a generic depends on the prescription, the approved product relationship and applicable state substitution rules. Patients should not change medication formulations independently or select a different strength based on cost.
Specific generic quotations belong in the generic Augmentin price guide. The brand Augmentin vs generic comparison explains product and regulatory distinctions without combining branded and generic offer records.
A cash price is the amount quoted under a cash-payment scenario, while an insured patient's out-of-pocket cost depends on the terms of the insurance benefit. Copays, coinsurance, deductibles, pharmacy networks and formulary restrictions may affect what the patient ultimately pays.
Insurance coverage can differ between original brand Augmentin and FDA-approved generic amoxicillin/clavulanate. A plan may apply different formulary tiers or require additional review for a brand-name prescription. A published cash estimate therefore cannot be used to predict the cost for an individual insured patient.
Discount-card pricing is another separate payment arrangement. Some programs offer reduced prices under specified pharmacy agreements or promotional conditions. An advertised discount may apply only to an approved generic, a particular quantity or participating pharmacies. Eligibility and program restrictions should be reviewed before treating a discount as an available price.
A comparison is most useful when the same prescription is evaluated under the available payment methods. The pharmacy and insurer can clarify applicable terms, but neither a generic coupon nor a brand list price establishes the final out-of-pocket cost in advance.
The Augmentin insurance coverage guide examines formulary and benefit considerations in greater depth. This section explains the payment categories needed to interpret a brand quotation accurately.
| Payment method | What the amount represents | Important qualification |
|---|---|---|
| Cash price | A pharmacy's quotation without using insurance benefits | May vary by product, quantity, pharmacy and location. |
| Insurance copay | A fixed patient payment under applicable plan terms | Depends on covered product and benefit requirements. |
| Coinsurance | A percentage-based patient payment | Depends on the plan's eligible cost-sharing calculation. |
| Deductible-stage payment | Patient responsibility affected by an unmet deductible | May differ from the amount paid after the deductible is met. |
| Prescription discount | An amount available under specific discount-program terms | May apply to generic rather than branded Augmentin. |
Pharmacy quotations may differ because of purchasing arrangements, product sourcing, local market conditions, dispensing practices and payment contracts. Consequently, a brand Augmentin amount observed at one pharmacy cannot be treated as a uniform U.S. retail price.
The exact dosage form and package quantity are also important. An original manufacturer package, a pharmacy-dispensed quantity and a liquid bottle after reconstitution may require different handling and pricing considerations. A quotation should therefore identify what the pharmacy proposes to dispense rather than merely stating Augmentin.
Brand availability introduces another variable. A product can remain FDA-approved and identifiable through published labeling without being stocked at every retail location. A pharmacy may need to check a supplier, and an online catalog entry should not be interpreted as confirmation that the branded product is immediately available.
Location-specific pricing comparisons should retain the pharmacy name, city or ZIP code, quote date and payment basis. Without those details, the numbers are difficult to interpret and may not be comparable. This page deliberately avoids ranking pharmacies or describing any retailer as the cheapest without current supporting evidence.
Questions about pharmacy legitimacy, valid prescriptions and online dispensing can be explored in the Augmentin online pharmacy guide. The Augmentin buying guide addresses prescription-based purchasing more broadly.
Augmentin XR is an extended-release tablet containing 1,000 mg of amoxicillin and 62.5 mg of clavulanic acid per tablet. It has different release characteristics from conventional Augmentin tablets and cannot be treated as interchangeable with immediate-release formulations. An ordinary 875 mg/125 mg tablet quotation does not establish the price of XR.
Augmentin XR also has a distinct FDA approval and relaunch history. Regulatory approval and published product identifiers do not establish current commercial distribution or local inventory. An XR pricing claim therefore requires verification of the actual extended-release product and its supply status.
Augmentin ES-600 is a separately labeled pediatric oral suspension containing 600 mg/42.9 mg per 5 mL after reconstitution. Its ingredient ratio and FDA-labeled use differ from standard oral suspension. A quotation for regular Augmentin liquid does not describe the cost of ES-600.
The Augmentin XR guide covers the extended-release product and its regulatory status. The Augmentin ES-600 guide explains the specialized pediatric formulation. Keeping these products separate prevents misleading comparisons and preserves the intended price-hub scope.
A useful Augmentin price comparison starts with an existing valid prescription. Before comparing quotations, the patient should identify whether the prescription specifies the original Augmentin brand or permits an appropriate generic, together with the exact two-component strength, dosage form and quantity.
The pharmacy quotation should identify the actual product rather than only the familiar brand name used in an online search. For branded products, manufacturer or labeler details and the relevant NDC may help distinguish the quoted item from a generic alternative. An NDC supports product identification but does not independently prove FDA approval, authenticity or inventory.
The next step is to establish the payment method. Cash, discount-card and insurance amounts can produce different results for the same prescription. A meaningful comparison keeps the payment basis consistent and records any program conditions that affect the amount.
The pharmacy location and quote date should also be retained. A product listing without a named pharmacy or current regional context may be useful as general information but cannot establish a reliable local retail comparison. If the original brand is unavailable, a proposed alternative requires professional review rather than self-directed substitution.
The checklist below provides a repeatable framework for evaluating quotations without publishing unverified price claims.
| Verification field | Information to confirm | Purpose |
|---|---|---|
| Prescription | Valid prescription and applicable brand or substitution instructions | Establishes the intended medicine. |
| Brand identity | Original Augmentin or specified approved generic | Prevents branded and generic prices from being confused. |
| Strength | Both amoxicillin and clavulanic-acid quantities | Distinguishes different combination formulations. |
| Dosage form | Conventional tablet, chewable or standard suspension | Prevents comparison of unrelated product forms. |
| Quantity | Tablet count or final liquid volume | Allows like-for-like price comparisons. |
| Pharmacy | Actual dispensing pharmacy and location | Provides geographic and service context. |
| Payment method | Cash, discount or insurance terms | Explains the basis of the quoted amount. |
| Quote date | Date the price was confirmed | Allows later verification when pricing changes. |
| Product availability | Whether the pharmacy can supply the intended prescription product | Separates a quotation from confirmed inventory. |
Augmentin is a prescription-only antibacterial medicine in the United States. A lower advertised price does not eliminate the requirement for an appropriate clinical evaluation and lawful dispensing. A website offering the medicine without a valid prescription should not be treated as evidence of legitimate access.
Cost considerations should not override the prescription's product requirements. Conventional tablets, chewable formulations, standard suspensions, Augmentin XR and Augmentin ES-600 have different labeled characteristics and substitution restrictions. Patients should not independently select another strength, combine tablets or estimate a liquid conversion to reduce expense.
Augmentin treats certain susceptible bacterial infections and does not treat viruses responsible for illnesses such as influenza or the common cold. Unnecessary antibiotic use can cause adverse reactions and contribute to antimicrobial resistance. Leftover antibiotic products should not be shared or reused for another illness.
The safest cost comparison identifies the prescribed medicine accurately and evaluates lawful pharmacy payment options without changing treatment independently. If affordability or product availability is a concern, the prescribing professional and pharmacist can review appropriate options under the applicable clinical and regulatory requirements.
This page provides durable guidance for understanding U.S. branded Augmentin costs. It does not publish unverifiable retail amounts, guarantee pharmacy stock or recommend a particular antibiotic regimen.
There is no single retail price that applies to every U.S. pharmacy. The amount depends on the exact branded formulation, strength, quantity, pharmacy, location and payment method. A current quotation for the prescribed product is needed to establish the applicable price.
The cost depends on whether the quoted product is original brand Augmentin or a generic, the prescribed tablet count, pharmacy, location and cash or insurance terms. A price displayed for generic amoxicillin/clavulanate should not automatically be treated as a brand quotation.
Not necessarily. The two strengths are distinct prescription products, and retail prices may vary by product availability, quantity and pharmacy. A meaningful comparison requires current quotations under comparable payment conditions. The strengths should not be exchanged independently to reduce cost.
Yes, strength can be one factor. Conventional Augmentin tablets include 250/125 mg, 500/125 mg and 875/125 mg presentations. Each has a different product identity, and the prescribed quantity and payment method can also affect the final price.
Liquid cost comparisons depend on the exact concentration, final prepared bottle volume, brand or generic identity and pharmacy terms. A price for one concentration or volume should not be assumed to apply to another product.
No such pricing equivalence should be assumed. Chewables are a separate dosage form with different strength pairs and formulation characteristics. Their costs require product-specific quotations.
Generic products may have different pricing arrangements from the original brand, but no universal price relationship should be assumed without current comparable quotations. Generic eligibility, pharmacy availability and payment terms must also be considered.
Prescription discount websites often use familiar brand names as search headings while displaying offers for generic alternatives. The actual selected medicine, strength and dosage form should be checked before interpreting the amount as a brand price.
Insurance may affect the patient's out-of-pocket cost, depending on the plan's formulary, cost sharing, deductible, pharmacy network and other requirements. Coverage for original brand Augmentin may differ from coverage for generic amoxicillin/clavulanate.
A cash price is quoted without applying insurance benefits. A copay is a patient payment determined by applicable insurance terms. Coinsurance and deductible requirements can produce other payment arrangements, so the amounts should not be treated as interchangeable.
Some discount programs may offer eligible prescription pricing, but coverage, pharmacy participation and whether the offer applies to the brand or generic must be verified. Discount-card terms can differ from insurance benefits and may include restrictions.
Pricing can vary because of purchasing arrangements, pharmacy location, product sourcing, available stock, payment contracts and dispensing quantity. A quote from one pharmacy is not necessarily representative of prices elsewhere.
No. A product listing, published price or FDA package record does not guarantee real-time inventory. The dispensing pharmacy must confirm whether the exact branded formulation and prescribed quantity can be supplied.
No. Augmentin XR is a distinct extended-release formulation containing 1,000 mg/62.5 mg per tablet. Its release characteristics, labeled status and commercial availability differ from those of conventional immediate-release Augmentin tablets.
No such equivalence should be assumed. ES-600 is a separate pediatric formulation containing 600 mg/42.9 mg per 5 mL after reconstitution. Its product identity and availability must be verified separately from standard Augmentin liquids.
Confirm the brand or generic designation, full two-component strength, dosage form, prescribed quantity, pharmacy location, payment method and quote date. Ask whether the exact product can actually be dispensed.
Patients should not independently change antibiotic strengths, tablet quantities or dosage forms. Augmentin products contain different proportions of amoxicillin and clavulanate, and some formulations are not interchangeable. Any proposed change requires professional assessment.
No. Augmentin is a prescription-only antibacterial medicine. Lawful dispensing requires a valid prescription and compliance with applicable pharmacy requirements. An advertised discount does not establish prescription-free access.